Immunic, Inc. Aktie News

Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about new positive data from the company's phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS). Proactive: Hello you're watching Proactive, I'm joined by Immunic CEO Dr Daniel Vitt.

Immunic Inc (NASDAQ:IMUX) released new long-term data from an ongoing study showing that its experimental drug, vidofludimus calcium, continues to help patients with relapsing-remitting multiple sclerosis (RRMS) over time. The biotech company said 92.3% of patients remained free of 12-week confirmed disability worsening (CDW) and 92.7% free of 24-week CDW at week 144, based on data representing...

– At Week 144, 92.3% of Patients Remained Free of 12-Week Confirmed Disability Worsening (CDW) With 92.7% Remaining Free of 24-Week CDW – – Vidofludimus Calcium Continues to Demonstrate Favorable Safety and Tolerability Profile; Long-Term Data Now Available up to 5.5 Years – NEW YORK , June 24, 2025 /PRNewswire/ --  Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pi...

Immunic AG / US4525EP1011

Immunic Inc (NASDAQ:IMUX) chief operating officer Jason Tardio talked with Proactive about the company's participation at the BIO International Convention in Boston and recent clinical developments. Tardio highlighted Immunic's ongoing business development efforts, particularly around its lead asset, vidofludimus calcium, aimed at treating multiple sclerosis (MS).

Immunic, Inc.'s CALLIPER study showed vidofludimus calcium reduced disability progression by 30% in PPMS patients, despite modest MRI results, suggesting strong neuroprotective effects. IMUX stock's significant drop appears to be an overreaction, given the positive disability progression data and clean safety profile. The company plans a Phase 3 trial focusing on confirmed disability progressio...

Immunic Inc (NASDAQ:IMUX)'s chief medical officer Dr Andreas Muehler talked with Proactive about the successful completion of patient enrollment for its Phase 3 ENSURE program targeting relapsing multiple sclerosis (MS). The ENSURE-1 and ENSURE-2 trials, described as "twin studies," have collectively enrolled over 2,000 patients across 15 countries.

Immunic Inc (NASDAQ:IMUX) has announced the completion of enrollment for both phase 3 ENSURE trials of its lead asset, vidofludimus calcium (IMU-838), in relapsing multiple sclerosis (RMS). The ENSURE program includes two identical, multicenter, randomized, double-blind phase 3 trials, ENSURE-1 and ENSURE-2, designed to assess the efficacy, safety, and tolerability of vidofludimus calcium compa...